{"id":"jw0201","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, JW0201 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of JW0201's interaction with SGLT2 are not well-documented.","oneSentence":"JW0201 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:04.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05814393","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2023-01-03","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT05814406","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2023-01-12","conditions":"Type 2 Diabetes Mellitus","enrollment":196},{"nctId":"NCT06361277","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2023-11-03","conditions":"Healthy","enrollment":56},{"nctId":"NCT05463497","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2022-01-17","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JW0201+C2022+C2204"],"phase":"phase_3","status":"active","brandName":"JW0201","genericName":"JW0201","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JW0201 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}